Mounjaro Flexpen 12.5 (Tirzepatide SOLUTION) 12.5mg

Mounjaro Flexpen 12.5mg delivers tirzepatide in a pre-filled pen for subcutaneous use. This GLP-1/GIP receptor agonist supports weight management and blood sugar control in adults. Ideal for convenient at-home dosing with temperature-sensitive storage. Prescription required.

Strength

12.5mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Lilly

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tirzepatide is used to improve blood sugar levels in adults with type 2 diabetes. It may also support weight management when combined with diet and exercise. People often ask, what is tirzepatide used for beyond diabetes care. The medication works by influencing hormones that regulate appetite and insulin.

Side Effects

Users commonly report reduced hunger and slower digestion after starting tirzepatide. Some notice improved energy levels and better glucose control within weeks. Mild side effects like nausea or stomach discomfort may occur early in treatment. These effects often lessen as the body adjusts to the medication.

Precautions & Warnings

Store the Flexpen between 2–8°C and protect from light. Do not freeze or expose to extreme heat. Keep pens in their original packaging until use. Dispose of used pens properly according to local guidelines. Always follow healthcare provider instructions for handling and storage.

Avoid Interactions

Alcohol may increase the risk of side effects like nausea or low blood sugar. Certain medications, such as insulin or sulfonylureas, may require dose adjustments when used with tirzepatide. Always inform your doctor about all prescriptions, over-the-counter drugs, and supplements. CYP inhibitors can affect how tirzepatide is processed in the body.

Frequently Asked Questions

Tirzepatide is used to improve blood sugar control in adults with type 2 diabetes and may support weight management.

The solution is injected under the skin, typically once weekly, as directed by a healthcare provider.

Tirzepatide requires a prescription and is available through licensed pharmacies or telehealth services.

Common side effects include nausea, stomach pain, or reduced appetite, especially when starting treatment.

Store the pen refrigerated between 2–8°C and use it within the specified time after first use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.